MAIA Biotechnology, Inc.
MAIA · XNYSCIK 1878313fmd_006YVVQKKVKJ4W8N8EVJ3TGSS2Manufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2021 to Sep 30, 2026, 23 periods
| Line item | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Total revenues | – | 0 | 0 | 0 | – |
| Research and development | 3 | 9 | 11 | 10 | 0 |
| Total operating expenses | 8 | 16 | 20 | 17 | 24 |
| Operating income | (8) | (16) | (20) | (17) | (24) |
| Interest expense | 1 | 0 | 0 | 0 | – |
| Interest and investment income | 0 | 0 | 0 | 0 | – |
| Income before taxes | (13) | (16) | (20) | (23) | (22) |
| Income tax expense | – | – | – | 0 | 0 |
| Net income from continuing operations | – | – | – | (23) | (22) |
| Net income | (13) | (16) | (20) | (23) | (22) |
| Net income to common shareholders | (13) | (16) | (20) | (23) | (22) |